"Corona vaccine ready in mid-November"

Several vaccine manufacturers and experts tell SVT that it is now in November and December that several vaccine manufacturers expect to be completely finished with the tests by the results in the so-called phase 3 studies being completed.

- There will be a lot of results now in November, says Matti Sällberg, vaccine researcher and professor at Karolinska Institutet.

The same picture is given by vaccine manufacturers that SVT spoke to.

- This is a marathon that has been going on for seven months.

In mid-November, we will be able to draw the final conclusions about efficacy and safety, says Mikael Dolsten, global research manager at the pharmaceutical company Pfizer, to SVT.

He says that Pfizer expects to submit a final application for approval of the vaccine in the second or third week of November, and that it can then go fast, as, among other things, it already has an open application process with the European Medicines Agency EMA.

Several vaccine manufacturers now claim to be in the very final phase of the tests required before the coronavirus vaccine can be approved by drug authorities.

The British-Swedish pharmaceutical manufacturer Astrazeneca, which has already signed a contract with the EU for deliveries, also says that the results required to be able to submit an application for approval are planned to come before the turn of the year.

- The last results from the tests with the vaccines on test subjects will come in November or December, this applies to most of the vaccine companies.

Tens of thousands of people have tested our vaccine so far, says Mene Pangalos, head of research at Astrazeneca to SVT.

In total, the ten vaccine projects that are in the phase of large-scale tests on humans have given corona vaccine to more than 100,000 people, says vaccine researcher Matti Sällberg to SVT.

Several of the pharmaceutical companies have also already built up stocks of vaccine doses in order to be able to start delivering quickly as soon as the approval comes.

- We have production in both Europe and the USA and in mid-November we will have millions of doses ready, says Pfizer's Mikael Dolsten.

- Astrazeneca has bought a license for our vaccine and they started large-scale production already this summer, says Sarah Gilbert, head of research for vaccine research at the University of Oxford.